Effectiveness and Durability of the BNT162b2 KP.2 Vaccine Against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Sara Y. Tartof, Timothy B. Frankland, J.M. Slezak, Bradley K. Ackerson, Laura Puzniak
DOI: 10.1093/ofid/ofag019
Cited by: 3
References: 6

Abstract

Vaccine effectiveness of BNT162b2 KP.2 vaccine against COVID-19 hospital admissions was 49% (95% CI, 30-63) and 45% (95% CI, 35-54) against emergency department/urgent care encounters (vs no KP.2 vaccine at 90 days from vaccination with some waning. Vaccine effectiveness remained high regardless of prior COVID-19 vaccination and among older adults.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research Vaccine Coverage and Hesitancy Immune responses and vaccinations

Publication details

Journal / source
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
13
Issue
2
Pages
ofag019–ofag019
Publication date
13 January 2026
Language
EN